AZD5423

AZD5423
Systematic (IUPAC) name
2,2,2-Trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide
Identifiers
ChemSpider 28536140
Chemical data
Formula C25H21F4N3O3
Molar mass 487.446 g/mol

AZD5423 is a nonsteroidal glucocorticoid and phase II drug by AstraZeneca disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.[1][2][3][4]

See also

References



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.